CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $71,715.00. Following the completion of the sale, the insider now owns 9,026 shares of the company’s stock, valued at $135,390. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) remained flat at $13.85 during midday trading on Friday. The company’s stock had a trading volume of 72,885 shares. The company’s market capitalization is $510.61 million. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $20.02. The stock has a 50 day moving average price of $14.71 and a 200-day moving average price of $14.49.
CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. Equities research analysts expect that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current year.
WARNING: “CytomX Therapeutics, Inc. (NASDAQ:CTMX) Insider Sells $71,715.00 in Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2802229/cytomx-therapeutics-inc-nasdaqctmx-insider-sells-71715-00-in-stock.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in CTMX. Russell Investments Group Ltd. purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $243,000. State Street Corp increased its position in shares of CytomX Therapeutics by 1.7% in the fourth quarter. State Street Corp now owns 275,483 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 4,596 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $1,002,000. Teachers Advisors LLC increased its position in shares of CytomX Therapeutics by 6.7% in the fourth quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 2,209 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $158,000. 52.33% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on CTMX. BidaskClub cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday. Bank of America Corporation reiterated a “buy” rating and issued a $30.00 price target (up from $28.00) on shares of CytomX Therapeutics in a research note on Wednesday. Cowen and Company reiterated a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $25.00 price target on shares of CytomX Therapeutics in a research note on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. CytomX Therapeutics has an average rating of “Hold” and a consensus price target of $25.60.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.